A randomized, double‐blind, placebo‐controlled, pharmacokinetic and pharmacodynamic study of a fixed‐dose combination of phentermine/topiramate in adolescents with obesity

Abstract

Treatment of adolescents with obesity using a fixed-dose combination of PHEN/TPM for 8 weeks resulted in exposure to PHEN and TPM that was comparable to that observed in adults, statistically significant weight loss, and a tolerable safety profile. These data indicate that both mid- and top-dose levels are appropriate for longer-term safety and efficacy studies in adolescents.